James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners
Latest from The University of Texas MD Anderson Cancer Center
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5